ArticleScientific reports2024
Comparative analysis of SARC-F-EBM, Ishii test, and six other screening tools for sarcopenia in Chinese community-dwelling older adults: a cross-sectional diagnostic study.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Uric acid to high-density lipoprotein cholesterol ratio as a novel biomarker for sarcopenia: a national study with machine learning insights.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Association of phase angle with malnutrition and sarcopenia in interstitial lung disease: a cross-sectional analysis of body composition and functional decline.BMC pulmonary medicine · 2026Observational
- Comparative Performance of SARC-F, SARC-CalF, SARC-F + EBM, and Ishii Score for Detecting Sarcopenia in Hospitalised Geriatric Patients.Journal of clinical medicine · 2026Article
- Availability and convenience of sarcopenia screening and diagnostic tools in Chinese primary care.Frontiers in public health · 2026Article
- Enhancing sarcopenia screening in primary care: a machine learning approach using simple physical tests vs. SARC-F in 2,788 community-dwelling older adults.Frontiers in public health · 2026Article
- The role of protein quality and amino acid composition in preventing sarcopenia and functional decline in older adults.Frontiers in nutrition · 2026Review
- Hierarchical Evaluation of Predictive Models for Confirmed Sarcopenia: Discrimination, Calibration, and Clinical Applicability in a Cross-Sectional Study of Older Adults.Journal of clinical medicine · 2025Article
- Amino acid metabolites as potential circulating biomarkers for sarcopenia.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the relative performance of simple screening methods for sarcopenia in Chinese community-dwelling older adults. Data of older adults aged ≥ 60 were collected through a cross-sectional investigation. Sarcopenia was defined according to the Asian Working Group for Sarcopenia 2019 criteria. The accuracy of screening methods was evaluated using sensitivity, specificity, receiver operating characteristic (ROC) curves and area under the ROC curves (AUC). The AUC value greater than 0.8 represented the good screening ability. A total of 918 older adults (44.3% men, mean age 70.4 ± 6.5 years) were included in this study. The overall prevalence rates of possible sarcopenia, confirmed sarcopenia, and severe sarcopenia were 59.5%, 12.8%, and 5.9%, respectively. In men, the SARC-F-EBM and Ishii tests indicated good screening capabilities for confirmed sarcopenia, with an AUC of 0.81 (95% CI: 0.77-0.85) and 0.80 (95% CI: 0.76-0.84), respectively. In women, the highest AUC was also achieved using the SARC-F-EBM at 0.79 (95% CI: 0.75-0.82), followed by the Ishii test at 0.77 (95% CI: 0.74-0.81), showing the moderate efficacy. A ranking diagram showed that SARC-F-EBM was most likely to be considered the best method for diagnosing sarcopenia in terms of AUC and sensitivity, regardless of sex. We recommend the SARC-F-EBM for sarcopenia screening in community-dwelling Chinese older adults when respondents are able to answer the questionnaire accurately; otherwise, the Ishii test consisting entirely of objective measures could be used.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.